References (published year) | Age | Sex | BMI | Preoperative radiation | Neoadjuvant chemotherapy | Robot generation† | Operative duration (min) | Amount of blood loss (ml) | T§ | N§ | M§ | Stage§ | RM (mm) | Complications (Clavien–Dindo classification) | Hospital stay after surgery (days) | Recurrence | Follow-up period (months) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shin JW. (2014) [12] | 41 | M | 18.0 | Yes | Yes | NA | 480 | 300 | cT4b | N2 | M0 | cIIIC | NA | None | 8 | NA | NA |
Winters BR. (2015) [13] | 61 | M | 24.0 | Yes | Yes (FOLFOXIRI) | Si | 570 | 350 | T4b | N2 | M0 | IIIC | NA | None | 7 | NA | NA |
Wiliams M. (2020) [14] | 46 | M | 18.1 | Yes | Yes (mFOLFOX6) | NA | 200 | NA | T4 | N2a | M1 | IV | 4.0 | UTI (II), ureteric stricture (IIIa) | 9 | Yes (not local) | 21 |
Stefan S (2022) [15] | 62 | M | 32.0 | Yes | Yes (capecitabine) | X | 400 | 100 | ypT4b | N1b | MX | ypIIIc | > 1.0 | ileus (II) and UTI (II) | 11 | NA | 1 |
Our case | 67 | M | 19.0 | Yes | Yes (tegafur/uracil) | Xi | 560 | 200 | ypT4b | N0 | M0 | ypIIc | 2.5 | unknown fever (II) | 21 | None | 24 |